IP Library Granted Patent US 9,730,960
Granted Patent B2
US 9,730,960 · App. 14/124,800 · Granted Aug 15, 2017

Method for treating or preventing graft versus host disease

Inventors: Douglas G. McFadden (Gainesville, FL); Eric C. Bartee (Gainesville, FL); Christopher R. Cogle (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc.
A61K35/28A61K35/14A61K35/17A61K35/768C12N5/0636A61K2035/122A61K2035/124C12N2710/24041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,730,960
App. No.
14/124,800
Granted
Aug 15, 2017
Kind
B2
Abstract

A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.

Claims (11)

1. A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells, the method comprising:

contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the subject following transplantation of the graft into the subject; and

after the contacting, transplanting the virus-treated graft into the subject,

wherein the graft comprises an allogeneic graft.

2. The method of claim 1 , wherein the transplanting comprises a technique from the group consisting of an allogeneic hematopoietic cell transplant, a donor cell infusion, and a supportive blood product transfusion.

3. The method of claim 1 , wherein the graft comprises bone marrow or human peripheral blood cells.

4. The method of claim 1 , wherein the T lymphocytes comprise CD3 + T lymphocytes.

5. The method of claim 1 , further comprising

administering at least one of chemotherapy, biotherapy, immunosuppression or radiotherapy to the host subject before transplanting the virus-treated graft into the subject.

6. The method of claim 5 , wherein the graft comprises at least one member from the group consisting of bone marrow and human peripheral blood cells.

7. The method of claim 5 , wherein the subject has a hematologic malignancy.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 16, 2015
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035443/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: MCFADDEN, DOUGLAS G.; BARTEE, ERIC C.; COGLE, CHRISTOPHER R.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 032180/0705 →
Continuity (2)
Provisional Application 61495342 · Jun 9, 2011
Related Publication 20140328804A1 · Nov 6, 2014